| Literature DB >> 34059242 |
Justin W Marson1, Margaret L Snyder2, Mark G Lebwohl2.
Abstract
Psoriasis is a systemic inflammatory condition that negatively affects the quality of life and medical health of 125 million individuals globally. Although psoriasis has historically been viewed as a skin-limited disease and managed with topical agents (eg, coal tar, corticosteroids, and vitamin D analogues), the recontextualization of psoriasis as a systemic condition involving multiple organ systems has prompted the development of numerous immunomodulating, systemic agents with more targeted mechanisms of action. This article briefly discusses the indications and nuances of new and developing therapeutic agents for psoriasis management.Entities:
Keywords: Aryl hydrocarbon receptor modulator; Biologics; Interleukins; Janus kinase inhibitor; Psoriasis; Therapy; Tumor necrosis factor-alpha; Tyrosine kinase inhibitor
Year: 2021 PMID: 34059242 DOI: 10.1016/j.mcna.2021.04.004
Source DB: PubMed Journal: Med Clin North Am ISSN: 0025-7125 Impact factor: 5.456